pharmaceutical investing CASI Pharmaceuticals Announces First Half 2026 Business and Financial Results
pharmaceutical investing CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel
pharmaceutical investing CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection
pharmaceutical investing CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia
pharmaceutical investing CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements
pharmaceutical investing CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology Annual Meeting
pharmaceutical investing CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results
pharmaceutical investing CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ
Steadright Critical Minerals Inc. to Acquire up to 75% Interest in the Péribonka Ree-Niobium Carbonatite Project, Saguenay-Lac-St-Jean Region, Québec
Prismo Metals Announces Listing of Blade Resources on the CSE Prismo Metals Owns 6,755,000 Shares of Blade Resources
Goldgroup Highlights Its Two Producing Mines and Significant Growth Potential Across the Don David Gold Complex in Mexico
